Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects

被引：0
|
作者：
Chanan Shaul
Simcha Blotnick
Mordechai Muszkat
Meir Bialer
Yoseph Caraco
机构：
[1] Hadassah-Hebrew University Medical Center,Clinical Pharmacology Unit, Division of Medicine
[2] Hebrew University,Institute of Drug Research, School of Pharmacy, Faculty of Medicine
来源：
Molecular Diagnosis & Therapy | 2017年 / 21卷
关键词：
Warfarin; Variant Allele; Warfarin Dose; Oral Clearance; CYP2C9 Genotype;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 83
页数：8
相关论文
共 50 条
  • [1] Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects
    Shaul, Chanan
    Blotnick, Simcha
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    MOLECULAR DIAGNOSIS & THERAPY, 2017, 21 (01) : 75 - 83
  • [2] The pharmacokinetics of S-warfarin in healthy subjects carrying different CYP2C9 genotypes.
    Shaoul, H.
    Blotnick, S.
    Muszkat, M.
    Caraco, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S19 - S19
  • [3] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [4] Novel CYP2C9 promoter polymorphisms are associated with lower S-warfarin clearance and dose requirements in patients
    Cavallari, L. H.
    Vaynshteyn, D.
    Freeman, K. M.
    PHARMACOGENOMICS, 2014, 15 (03) : 262 - 262
  • [5] Prediction of the oral clearance of S-warfarin in CYP2C9 genotypes from in vitro enzyme kinetic data
    Almond, Lisa M.
    Rowland-Yeo, Karen
    Howgate, Eleanor M.
    Tucker, Geoff T.
    Rostami-Hodjegan, A.
    DRUG METABOLISM REVIEWS, 2006, 38 : 92 - 93
  • [6] Maintenance warfarin dose in children is determined by S-warfarin clearance which is in turn influenced by CYP2C9 genotype
    Biss, T.
    Avery, P.
    Ibubeleye, V.
    Swinburne, E.
    Kamali, F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 8 - 8
  • [7] ASSOCIATION OF CYP2C9 AND VKORC1 SNPS ON S-WARFARIN CLEARANCE IN AFRICAN AMERICANS
    Hernandez, W.
    Aquino-Michaels, K.
    Perera, M. A.
    Patel, S.
    Jeong, H.
    Cavallari, L. H.
    Takahashi, H.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2014, 62 (04) : 729 - 729
  • [8] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    Scordo, MG
    Pengo, V
    Spina, E
    Dahl, ML
    Gusella, M
    Padrini, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 702 - 710
  • [9] Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism of S-Warfarin
    Jones, Drew R.
    Kim, So-Young
    Guderyon, Michael
    Yun, Chul-Ho
    Moran, Jeffery H.
    Miller, Grover P.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2010, 23 (05) : 939 - 945
  • [10] 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients
    Takahashi, H
    Ieiri, I
    Wilkinson, GR
    Mayo, G
    Kashima, T
    Kimura, S
    Otsubo, K
    Echizen, H
    BLOOD, 2004, 103 (08) : 3055 - 3057
12345